<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS/HYPOTHESIS: The leading cause of <z:hpo ids='HP_0011420'>death</z:hpo> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We examined the prevalence of <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischaemia</z:e> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients and tried to establish an algorithm to identify patients with a high risk of <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">ischaemic heart disease</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients who had no known or suspected <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>, and had been referred consecutively to a <z:mp ids='MP_0002055'>diabetes</z:mp> clinic for the first time (n=305; age 58.6+/-11.3 years; <z:mp ids='MP_0002055'>diabetes</z:mp> duration 4.5+/-5.3 years) were screened for <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischaemia</z:e> using myocardial perfusion scintigraphy (MPS) </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The univariate predictors of <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischaemia</z:e> were: atypical or typical <z:hpo ids='HP_0001681'>angina pectoris</z:hpo>, two or more traditional risk factors for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CVD</z:e>, BMI &gt;32 kg/m2, systolic blood pressure &gt;140 mmHg, HbA1c &gt;8.5%, high-sensitivity C-reactive protein &gt;4.0 mg/l, N-terminal pro-brain natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> &gt;300 pg/ml, left atrial volume index &gt;32 ml/m2, left ventricular ejection fraction &lt;50%, and carotid and <z:hpo ids='HP_0004950'>peripheral arterial disease</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>The algorithm identified low (n=96), intermediate (n=65) and high risk groups (n=115), in which the prevalence of <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischaemia</z:e> was 15%,23% and 43%, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>Overall the algorithm reduced the number of patients referred to MPS from 305 to 144.However, the sensitivity and specificity of the algorithm was just 68% and 62%, respectively.CONCLUSIONS/INTERPRETATION: Our algorithm was able to stratify which patients had a low, intermediate or high risk of <z:e sem="disease" ids="C0151744" disease_type="Disease or Syndrome" abbrv="IHD">myocardial ischaemia</z:e> based on MPS </plain></SENT>
<SENT sid="6" pm="."><plain>However, the algorithm had low sensitivity and specificity, combined with high cost and time requirements.Trial registration: clinicaltrials.gov NCT00298844 Funding: The study was funded by the Danish Cardio vascular Research Academy (DaCRA), The Danish <z:mp ids='MP_0002055'>Diabetes</z:mp> Association and The Danish Heart Foundation </plain></SENT>
</text></document>